Werfen and Oxford Nanopore collaborate to enhance transplant testing
Werfen and Oxford Nanopore Technologies have expanded their collaboration to validate Werfen’s transplant assays on Oxford Nanopore’s sequencing platforms, aiming to deliver faster, more accurate donor-recipient matching.
Werfen announced a strategic collaboration with Oxford Nanopore Technologies to validate Werfen’s specialized transplant assay portfolios for use on Oxford Nanopore’s sequencing platforms.
Building on a collaboration between Werfen and Oxford Nanopore that began in 2020, this marks a significant milestone, combining Werfen’s validated, high-precision transplant assays with Oxford Nanopore’s rapid, information-rich sequencing technology. Together, the companies aim to streamline laboratory workflows, providing a fast and accurate "DNA-to-result" experience that leverages the speed and scalability of nanopore sequencing.
By ensuring the optimization and compatibility of Werfen’s transplant portfolio, including solutions for Human Leukocyte Antigen (HLA) typing and pre-transplant matching, with Oxford Nanopore’s platforms, the aim is to enable laboratories to implement high-quality testing with reduced complexity and faster results. This is particularly critical in transplantation, where rapid, high-resolution data is essential for donor-recipient matching and long-term success.
